Navigation Links
AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
Date:1/28/2010

LONDON, January 28 /PRNewswire-FirstCall/ -- Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David Brennan saying in a video interview on http://www.cantos.com that cost control and restructuring had helped deliver a revenue line above company expectations.

In the video Mr Brennan looks at the results and the drivers behind a 23% rise in core operating profit and, significantly, a 12% dividend increase. He discusses the rationale behind the "significant" R&D changes that the company is implementing as well as progress on the ongoing restructuring programme and where he sees future growth and opportunities coming from.

While he says the next five years will be challenging, the long-term future looks strong.

"We're entering a period of time where we are launching new products and we're excited about them, but it's going to take a few years for those products to get up to the revenue contribution that we need that will balance some of the patent expirations."

The interview and transcript are available now on http://www.cantos.com/company/astrazeneca.

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email amanda.alexander@cantos.com or phone +44-207-936-1352.

SOURCE AstraZeneca Plc


'/>"/>
SOURCE AstraZeneca Plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
2. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
3. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
4. BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
5. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
6. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
7. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
8. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
9. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
10. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
11. Melior Enters Research Collaboration with AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s ... in San Francisco. Located at booth number 7301, representatives from the Thai Government, ... discuss the Thai biotechnology and life sciences sector. , Deputy Secretary General ...
(Date:5/25/2016)... ... 2016 , ... Scientists at the University of Athens say they have evidence ... hampering the research that could lead to one good one. Surviving Mesothelioma has just ... , The team evaluated 98 mesothelioma patients who got a second ...
(Date:5/24/2016)... Mass. (PRWEB) , ... May 24, 2016 , ... ... heart attacks, diabetes, and traumatic injuries, will be accelerated by research at Worcester ... cells into engines of wound healing and tissue regeneration. , The novel method, ...
(Date:5/23/2016)... ... ... need for blood donations in South Texas and across the nation is growing. , But ... blood donations are on the decline. In fact, donations across the country are at their ... Texas in the last four years alone. , There is no substitute for blood. , ...
Breaking Biology Technology:
(Date:3/11/2016)... 2016 http://www.apimages.com ) - --> ... available at AP Images ( http://www.apimages.com ) - ... to produce the new refugee identity cards. DERMALOG will be unveiling ... in Hanover next week.   --> ... used to produce the new refugee identity cards. DERMALOG will be ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI ... categories of Innovation, Research & Development, Leadership in Education, ... This is the 9 th year of the ... of companies and individuals from past years . ... on a pre-described set of criteria, by a panel ...
Breaking Biology News(10 mins):